Lineage Cell Therapeutics (LCTX) Non-Current Assets (2010 - 2026)

Lineage Cell Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $53.4 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 13.6% year-over-year to $53.4 million in Q1 2026; TTM through Mar 2026 was $201.1 million, a 19.09% decrease from a year earlier, with the FY2025 full-year figure at $53.4 million, down 14.13% from the prior year.
• Non-Current Assets held at $53.4 million in Q1 2026 per LCTX's latest filing, from $53.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $63.7 million in Q4 2022 and bottomed at $47.0 million in Q2 2025.
• The 5-year median for Non-Current Assets is $62.4 million (2024), against an average of $59.7 million.
• Across the five-year window, Non-Current Assets advanced 2.1% in 2023 and slipped 24.77% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $63.7 million in 2022, then retreated by 1.71% to $62.6 million in 2023, then retreated by 0.57% to $62.2 million in 2024, then dropped by 14.13% to $53.4 million in 2025, then slipped by 0.11% to $53.4 million in 2026.
• Per Business Quant, the three latest LCTX Non-Current Assets figures stand at $53.4 million (Q1 2026), $53.4 million (Q4 2025), and $47.4 million (Q3 2025).